Val completed her undergraduate degree and PhD in psychology at Manchester University. Her PhD looked at cognitive changes with normal ageing. Her research career has included adult psychosocial oncology, child health and childhood disability. She has worked on a number of projects in psychosocial oncology including studies looking at the impact of chemotherapy and hormone therapies on cognitive function, and the development and validation of patient reported outcome measures for cancer patients and their caregivers. Most recently Val has been Programme Manager for the national Cancer Quality of Life Survey at the NHS Cancer Programme. She re-joined SHORE-C in April 2023
There is interest worldwide about using a drug called a PARP inhibitor (PARPi) in people with BRCA 1 or BRCA 2 gene changes. These drugs already work in patients with cancer who have gene changes. We hope that PARP inhibitors given to those with gene changes who do not have cancer will stop a cancer developing. Before doctors can design a chemoprevention trial using this drug, we need to find out the preferences and acceptability of such a study. Initial insights gained from members of the public - in this instance women - will help with trial design and the sort of information required.
Nelson D, Pickwell-Smith B, Falvey J, Kane R, Cooke S, McPeake K...Shilling V...Lawler M (2026) Coastal cancer care: A blueprint to address the unmet needs through place-based research and policy approaches. Journal of Cancer Policy. Volume 49 Article 100769. Find it online here
29/06/2026
Nielsen, I.H., Landbo, C., Rosenberg, T., Piil, K.,Tolver, A., Shilling, V., Jarden, M. (2026) Psychometric validation of the Danish cancer caregiver roles and responsibilities scale. Quality of Life Research 35, 126. https://doi.org/10.1007/s11136-026-04234-8 Find it online here
01/04/2026
Hunter R, Jenkins V, Fallowfield L, Jones J & Shilling V. (2025). Patient and caregiver understanding of multiple myeloma: A scoping review. European Journal of Oncology Nursing,
Volume 79, 102992, ISSN 1462-3889 Find it online here
04/10/2025
Wheelwright, S., Lean, Q.Y., Minton, O., Shilling, V. The use of patient reported outcome measures in routine cancer clinical care: results from a freedom of information request. Discov Health Systems 4, 64 (2025). Https://doi.org/10.1007/s44250-025-00250-6 Find it online here
03/06/2025
Starkings R, Harder H, Fallowfield L, Shilling V. (2025) Exploring the real-world experience of abemaciclib treatment for HR +, HER2- metastatic breast cancer - a qualitative analysis of the IMPACTOR study. Supporive Care in Cancer; 33 (421). Find it online here
26/04/2025
Harder H, Starkings R, Fallowfield L, May S, & Shilling V. (2025) Incidence and management of diarrhoea associated with abemaciclib and endocrine therapy for hormone-receptor positive, HER2-negative metastatic breast cancer: the UK patients' experiences. Support Care Cancer 33, 422. Find it online here
26/04/2025
Wheelwright S, Minton O, Absolom K, Fairvre-Finn C, Fallowfield L, Gilbert ...Shilling V. (2025) Integrating ePROMs: A Key Opportunity for England's National Cancer Plan. Journal of Cancer Policy (44): 100575 Find it online here
10/03/2025
Shilling, V., Starkings, R. & Fallowfield, L. Feasibility and acceptability of a virtual learning module for navigating angry conversations in clinical encounters. BMC Med Educ 25, 167 (2025). https://doi.org/10.1186/s12909-025-06726-6 Find it online here
01/02/2025
Fallowfield L, Starkings R, Palmieri C, Tait, A, Stephen L, May S, ... & Jenkins V. (2023). Living with metastatic breast cancer (LIMBER): experiences, quality of life, gaps in information, care and support of patients in the UK. Supportive Care in Cancer; 31(8): 459. Find it online here
11/07/2023
Botham J, Shilling V, & Jones J. (2021). Patient and public understanding of the concept of 'personalised medicine' in relation to cancer treatment: A systematic review. Future Healthcare Journal; 8(3): e703. Find it online here
29/11/2021